Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Peggy Lyons"'
Autor:
Carey, Anders, P Kelly, Marcom, Bercedis, Peterson, Lin, Gu, Sue, Unruhe, Renee, Welch, Peggy, Lyons, Millie, Behera, Susannah, Copland, Gretchen, Kimmick, Heather, Shaw, Stacey, Snyder, Monica, Antenos, Teresa, Woodruff, Kimberly, Blackwell
Publikováno v:
Cancer Investigation. 26:286-295
Premenopausal women treated for early stage breast cancer (ESBC) are at risk for chemotherapy-related amenorrhea (CRA). Prospectively-validated, predictive markers of CRA are needed.Premenopausal women with ESBC and planned chemotherapy (/= 25% risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47d974346538425fa0b3aa3163c19475
https://doi.org/10.1080/07357900701829777
https://doi.org/10.1080/07357900701829777
Autor:
James J. Vredenburgh, John H. Sampson, Sridharan Gururangan, Annick Desjardins, Roger E. McLendon, James M. Provenzale, David A. Reardon, Alan Swaisland, Allan H. Friedman, James E. Herndon, Jeremy N. Rich, Sith Sathornsumetee, Jeannette M. Dowell, Jennifer A. Quinn, Sandy Tourt-Uhlig, Robert Smith, Judith S. Ochs, Peggy Lyons, Darell D. Bigner, Henry S. Friedman
Publikováno v:
Clinical Cancer Research. 12:860-868
Purpose: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the mammalian target of rapamycin, amo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54a503381ae1bd14f74c63fc3ebddeaf
https://doi.org/10.1158/1078-0432.ccr-05-2215
https://doi.org/10.1158/1078-0432.ccr-05-2215
Autor:
Susannah D. Copland, P. Kelly Marcom, Renee Welch, Kimberly L. Blackwell, Peggy Lyons, Gretchen Kimmick, Sue Unruhe, Carey K. Anders, Monica Antenos, Bercedis Peterson, Millie A. Behera, Lin Gu, Stacey A. Snyder, Heather S. Shaw, Teresa K. Woodruff
Publikováno v:
Cancer Investigation. 26:1068-1068
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8854f653e224a45828cd6306a8a90340
https://doi.org/10.1080/07357900802660220
https://doi.org/10.1080/07357900802660220
Autor:
Henry S. Friedman, David A. Reardon, A. Desjardins, Peggy Lyons, Jeremy N. Rich, Sridharan Gururangan, Sith Sathornsumetee, Darrell D. Bigner, James J. Vredenburgh, Jennifer A. Quinn
Publikováno v:
Journal of Clinical Oncology. 23:1565-1565
1565 Abnormal signaling of the PI3K/Akt pathway is a hallmark of malignant glioma. The primary objective of this phase 1 study is to determine the maximum tolerated dose (MTD) and dose-limiting tox...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::111d01753ef8349dce0abb3229c874de
https://doi.org/10.1200/jco.2005.23.16_suppl.1565
https://doi.org/10.1200/jco.2005.23.16_suppl.1565
Autor:
A. Salvado, Sith Sathornsumetee, Jennifer A. Quinn, David A. Reardon, James J. Vredenburgh, Jeremy N. Rich, A. Desjardins, Henry S. Friedman, Sridharan Gururangan, Peggy Lyons
Publikováno v:
Journal of Clinical Oncology. 23:1540-1540
1540 Imatinib mesylate (Gleevec), an inhibitor of the PDGF receptor tyrosine kinase with anti-angiogenic activity, has been shown to decrease tumor interstitial pressure resulting in enhanced delivery of cytotoxic therapy. The current phase I study i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::234ebffe340de168b1015aa3f80a939f
https://doi.org/10.1200/jco.2005.23.16_suppl.1540
https://doi.org/10.1200/jco.2005.23.16_suppl.1540